Outcome of infection with omicron SARS‐CoV ‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas

(2022) Paul A. Christensen et al.   AMERICAN JOURNAL OF PATHOLOGY

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

(2022) Obbina Abani et al.   LANCET

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants

(2022) Hung Fu Tseng et al.   NATURE MEDICINE

Patients with CLL have lower risk of death from COVID-19 in the omicron era

(2022) Carsten Utoft Niemann et al.   BLOOD

Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study

(2022) Tommy Nyberg et al.   LANCET

Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies

(2022) Timothée Bruel et al.   NATURE MEDICINE

Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study

(2022) Adam S Lauring et al.   BMJ-British Medical Journal

Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease

(2021) Thomas A. Ollila et al.   JAMA Oncology

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

(2021) Livio Pagano et al.   Journal of Hematology & Oncology